secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-323706
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027
--------------------------------------------------------------------------------

- Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.
- Pricing was at a premium to prior 5-day closing price on Nasdaq.
- Investors include ADAR1 Capital, Coastlands, Invus, RTW, Samsara BioCapital, Woodline Partners.
- Proceeds to advance TH103 for neovascular AMD and for working capital; cash runway to Q3 2027.
- Private placement expected to close Dec 19, 2025; registration rights to file after April 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/d48530d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-323706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer